A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
AstraZeneca
Study ID
NCT07073547
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AZD0120 — BIOLOGICAL
    AZD0120 is a BCMA/CD19 dual CAR T cell product under investigation for early-line treatment in subjects with multiple myeloma

Study Details

This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).

Key Dates

Start date
Jul 31, 2025
Status verified
May 2026
Primary completion
May 26, 2028
Completion
May 26, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: AZD0120
    AZD0120 will be administrated in one infusion

Primary Outcome Measure

Adverse Events (AEs) [ Time Frame: 2 years ]

Central Contacts

Locations (13)

FacilityCityStateZIPSite coordinators
Research SitePhoenixArizona85054-
Research SiteDuarteCalifornia91010-
Research SiteDenverColorado80218-
Research SiteTampaFlorida33612-
Research SiteAtlantaGeorgia30322-
Research SiteIowa CityIowa52242-
Research SiteRochesterMinnesota55905-
Research SiteSt LouisMissouri63110-
Research SiteNew YorkNew York10016-
Research SiteNashvilleTennessee37203-
Research SiteDallasTexas75235-
Research SiteHoustonTexas77030-
Research SiteCharlottesvilleVirginia22903-

Find similar trials in Phoenix, AZ

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Research Site· Phoenix, AZResearch Site· Duarte, CAResearch Site· Denver, COResearch Site· Tampa, FLResearch Site· Atlanta, GAResearch Site· Iowa City, IA

Related Studies